Phase I study of phenylacetate administered twice daily to patients with cancer.

Autor: Thibault, Alain, Samid, Dvorit, Cooper, Michael R., Figg, William D., Tompkins, Anne C., Patronas, Nicholas, Headlee, Donna J., Kohler, David R., Venzon, David J., Myers, Charles E., Thibault, A, Samid, D, Cooper, M R, Figg, W D, Tompkins, A C, Patronas, N, Headlee, D J, Kohler, D R, Venzon, D J, Myers, C E

Publikováno v: Cancer (0008543X); Jun1995, Vol. 75 Issue 12, p2932-2938, 7p

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

Autor: Humphrey, R. W., Wyvill, K. M., Nguyen, B.-Y., Shay, L. E., Kohler, D. R., Steinberg, S. M., Ueno, T., Fukasawa, T., Shintani, M., Hayashi, H.

Publikováno v: Antiviral Research; 1999, Vol. 41 Issue: 1 p21-34, 14p

Standardizing the expression and nomenclature of cancer treatment regimens. American Society of Health-System Pharmacist (ASHP), American Medical Association (AMA), American Nurses Association (ANA).

Autor: Kohler, D R, Montello, M J, Green, L, Huntley, C, High, J L, Fallavollita, A, Goldspiel, B R

Publikováno v: American Journal of Health-System Pharmacy; January 1998, Vol. 55 Issue: 2 p137-144, 8p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Autor: Figg WD; Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. wdfigg@helix.nih.gov, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2001 Jul; Vol. 7 (7), pp. 1888-93.